- Published on
Ophthalmology – Central Serous Chorioretinopathy (CSCR)
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by accumulation of fluid under the neurosensory retina, most commonly affecting the macula. This results from leakage of fluid through defects in the retinal pigment epithelium (RPE), often associated with small pigment epithelial detachments. The condition typically presents with a localized serous retinal detachment, and in rare cases, a more extensive “bullous” variant may occur with large shifting subretinal fluid. CSCR primarily affects otherwise healthy adults and is usually limited to the eye without systemic ocular involvement.
Epidemiologically, CSCR occurs predominantly in men between 25 and 50 years of age, with a strong male predominance (approximately 6:1). It is relatively uncommon but not rare, and recurrence occurs in about 30% of patients, sometimes years after the initial episode. Risk factors include corticosteroid use (in any form), psychological stress, and so-called “type A” personality traits. Conditions associated with elevated endogenous corticosteroids, such as Cushing’s disease, are also linked to CSCR.
The underlying pathophysiology involves dysfunction of the retinal pigment epithelium, allowing fluid from the choroid to pass into the subretinal space. Although the exact mechanism remains unclear, corticosteroids are believed to alter choroidal circulation and RPE permeability. The result is a serous detachment of the sensory retina, often centered at the macula, which leads to visual symptoms.
Patients typically present with blurred central vision, often described as a gray or dark spot (central scotoma). Visual distortion (metamorphopsia) and perception of objects appearing smaller than normal (micropsia) are common. Some patients report a history of recent emotional stress or corticosteroid exposure. On examination, a well-defined serous detachment of the macula is seen, sometimes with subretinal deposits. Importantly, the absence of hemorrhage helps distinguish CSCR from conditions like neovascular age-related macular degeneration.
Diagnosis is confirmed with imaging. Fluorescein angiography reveals focal leakage at the level of the RPE, often demonstrating a characteristic “smokestack” or “inkblot” pattern of dye diffusion. Optical coherence tomography (OCT) is especially useful, showing a dome-shaped elevation of the neurosensory retina with underlying RPE detachment. These imaging modalities are essential both for diagnosis and monitoring.
Management is often conservative, as approximately 85% of cases resolve spontaneously within 3–4 months with reabsorption of subretinal fluid. Observation is therefore the first-line approach in most patients. If the condition persists beyond several months or significantly affects vision, treatment options include focal laser photocoagulation to seal leakage sites or photodynamic therapy (especially when leakage is close to the fovea). Intravitreal anti-VEGF therapy, such as bevacizumab, has shown some benefit in selected cases.
The prognosis for CSCR is generally favorable, with over 90% of patients recovering visual acuity of 20/30 or better within 6 months. However, recurrent or chronic cases may lead to persistent RPE changes, subretinal fluid, and gradual visual decline. Long-term complications can include reduced visual acuity and, rarely, development of choroidal neovascularization. Regular follow-up is important, particularly in patients with recurrent disease or ongoing risk factors.
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by accumulation of fluid under the neurosensory retina, most commonly affecting the macula. This results from leakage of fluid through defects in the retinal pigment epithelium (RPE), often associated with small pigment epithelial detachments. The condition typically presents with a localized serous retinal detachment, and in rare cases, a more extensive “bullous” variant may occur with large shifting subretinal fluid. CSCR primarily affects otherwise healthy adults and is usually limited to the eye without systemic ocular involvement.
Epidemiologically, CSCR occurs predominantly in men between 25 and 50 years of age, with a strong male predominance (approximately 6:1). It is relatively uncommon but not rare, and recurrence occurs in about 30% of patients, sometimes years after the initial episode. Risk factors include corticosteroid use (in any form), psychological stress, and so-called “type A” personality traits. Conditions associated with elevated endogenous corticosteroids, such as Cushing’s disease, are also linked to CSCR.
The underlying pathophysiology involves dysfunction of the retinal pigment epithelium, allowing fluid from the choroid to pass into the subretinal space. Although the exact mechanism remains unclear, corticosteroids are believed to alter choroidal circulation and RPE permeability. The result is a serous detachment of the sensory retina, often centered at the macula, which leads to visual symptoms.
Patients typically present with blurred central vision, often described as a gray or dark spot (central scotoma). Visual distortion (metamorphopsia) and perception of objects appearing smaller than normal (micropsia) are common. Some patients report a history of recent emotional stress or corticosteroid exposure. On examination, a well-defined serous detachment of the macula is seen, sometimes with subretinal deposits. Importantly, the absence of hemorrhage helps distinguish CSCR from conditions like neovascular age-related macular degeneration.
Diagnosis is confirmed with imaging. Fluorescein angiography reveals focal leakage at the level of the RPE, often demonstrating a characteristic “smokestack” or “inkblot” pattern of dye diffusion. Optical coherence tomography (OCT) is especially useful, showing a dome-shaped elevation of the neurosensory retina with underlying RPE detachment. These imaging modalities are essential both for diagnosis and monitoring.
Management is often conservative, as approximately 85% of cases resolve spontaneously within 3–4 months with reabsorption of subretinal fluid. Observation is therefore the first-line approach in most patients. If the condition persists beyond several months or significantly affects vision, treatment options include focal laser photocoagulation to seal leakage sites or photodynamic therapy (especially when leakage is close to the fovea). Intravitreal anti-VEGF therapy, such as bevacizumab, has shown some benefit in selected cases.
The prognosis for CSCR is generally favorable, with over 90% of patients recovering visual acuity of 20/30 or better within 6 months. However, recurrent or chronic cases may lead to persistent RPE changes, subretinal fluid, and gradual visual decline. Long-term complications can include reduced visual acuity and, rarely, development of choroidal neovascularization. Regular follow-up is important, particularly in patients with recurrent disease or ongoing risk factors.
- Published on
Ophthalmology – Central Corneal Ulcers (Keratitis)
Central corneal ulcers are characterized by a localized epithelial defect accompanied by inflammation and destruction of the underlying corneal stroma. They are commonly referred to as corneal infiltrates or keratitis and may be either infectious or noninfectious. These ulcers are clinically significant because involvement of the central visual axis can rapidly lead to vision loss if not treated promptly.
The incidence of bacterial keratitis is substantial, with tens of thousands of cases occurring annually, particularly among contact lens users. Risk factors include contact lens wear (especially poor hygiene or overwear), ocular surface disease, inadequate eyelid closure, corneal hypoesthesia, and systemic autoimmune conditions. Preventive strategies focus on maintaining proper contact lens hygiene, preserving epithelial integrity, ensuring adequate lubrication, correcting eyelid abnormalities, and controlling underlying inflammatory or autoimmune diseases.
The pathophysiology begins with disruption of the corneal epithelium, which allows microorganisms or inflammatory processes to penetrate the stroma. This triggers a strong inflammatory response dominated by neutrophils, along with enzymatic degradation of the extracellular matrix through proteolytic enzymes such as matrix metalloproteinases. This process can lead to stromal thinning, ulceration, and even perforation if untreated.
Etiologically, central corneal ulcers may be infectious—caused by bacteria, fungi, viruses, or Acanthamoeba—or noninfectious, such as neurotrophic keratitis, exposure keratopathy, or autoimmune-related corneal melting. Infectious ulcers are frequently associated with contact lens misuse or trauma, whereas sterile ulcers are more commonly linked to systemic autoimmune diseases like rheumatoid arthritis or systemic lupus erythematosus.
Patients typically present with pain, redness, tearing, photophobia, and decreased vision. A detailed history is essential, especially regarding contact lens use, hygiene practices, water exposure, trauma, and systemic disease. On examination, findings include conjunctival injection, epithelial defects visible with fluorescein staining, stromal infiltrates, corneal thinning, and anterior chamber inflammation such as cells, flare, or hypopyon. Eyelid abnormalities and tear film insufficiency should also be assessed.
Diagnosis relies on clinical examination and microbiological evaluation. Central ulcers should be cultured before initiating antibiotic therapy. Corneal scrapings are obtained from the ulcer margin and inoculated onto appropriate media to identify bacterial, fungal, or protozoal pathogens. Special stains such as Gram stain, Giemsa, acid-fast stain, and calcofluor white may aid in identifying organisms. Additional tools like confocal microscopy can be useful, particularly in suspected Acanthamoeba infections. If the ulcer does not respond to treatment, corneal biopsy may be necessary.
Management requires urgent and aggressive therapy. First-line treatment for suspected bacterial ulcers involves intensive topical antibiotics, typically fourth-generation fluoroquinolones administered frequently, even hourly. Severe or resistant cases may require fortified antibiotics such as vancomycin combined with tobramycin or ceftazidime. Therapy should be adjusted based on culture results. If the ulcer is unresponsive or atypical, alternative diagnoses such as fungal or Acanthamoeba keratitis must be considered, and appropriate antifungal or anti-protozoal agents initiated.
Adjunctive therapy includes cycloplegic agents to relieve pain and prevent synechiae, as well as lubricating ointments to support epithelial healing. Systemic therapy may be required in certain infections, such as Neisseria or severe fungal disease. Referral to a cornea specialist is indicated if the ulcer is central, progressive, unresponsive to treatment within 24–48 hours, or difficult to culture.
Close follow-up is essential, typically on a daily basis until the ulcer stabilizes. Signs of improvement include re-epithelialization, reduction in infiltrate density, resolution of hypopyon, stabilization of corneal thickness, and improvement in visual acuity and symptoms. Early and appropriate management is critical to prevent complications such as corneal scarring, perforation, and permanent vision loss.
Central corneal ulcers are characterized by a localized epithelial defect accompanied by inflammation and destruction of the underlying corneal stroma. They are commonly referred to as corneal infiltrates or keratitis and may be either infectious or noninfectious. These ulcers are clinically significant because involvement of the central visual axis can rapidly lead to vision loss if not treated promptly.
The incidence of bacterial keratitis is substantial, with tens of thousands of cases occurring annually, particularly among contact lens users. Risk factors include contact lens wear (especially poor hygiene or overwear), ocular surface disease, inadequate eyelid closure, corneal hypoesthesia, and systemic autoimmune conditions. Preventive strategies focus on maintaining proper contact lens hygiene, preserving epithelial integrity, ensuring adequate lubrication, correcting eyelid abnormalities, and controlling underlying inflammatory or autoimmune diseases.
The pathophysiology begins with disruption of the corneal epithelium, which allows microorganisms or inflammatory processes to penetrate the stroma. This triggers a strong inflammatory response dominated by neutrophils, along with enzymatic degradation of the extracellular matrix through proteolytic enzymes such as matrix metalloproteinases. This process can lead to stromal thinning, ulceration, and even perforation if untreated.
Etiologically, central corneal ulcers may be infectious—caused by bacteria, fungi, viruses, or Acanthamoeba—or noninfectious, such as neurotrophic keratitis, exposure keratopathy, or autoimmune-related corneal melting. Infectious ulcers are frequently associated with contact lens misuse or trauma, whereas sterile ulcers are more commonly linked to systemic autoimmune diseases like rheumatoid arthritis or systemic lupus erythematosus.
Patients typically present with pain, redness, tearing, photophobia, and decreased vision. A detailed history is essential, especially regarding contact lens use, hygiene practices, water exposure, trauma, and systemic disease. On examination, findings include conjunctival injection, epithelial defects visible with fluorescein staining, stromal infiltrates, corneal thinning, and anterior chamber inflammation such as cells, flare, or hypopyon. Eyelid abnormalities and tear film insufficiency should also be assessed.
Diagnosis relies on clinical examination and microbiological evaluation. Central ulcers should be cultured before initiating antibiotic therapy. Corneal scrapings are obtained from the ulcer margin and inoculated onto appropriate media to identify bacterial, fungal, or protozoal pathogens. Special stains such as Gram stain, Giemsa, acid-fast stain, and calcofluor white may aid in identifying organisms. Additional tools like confocal microscopy can be useful, particularly in suspected Acanthamoeba infections. If the ulcer does not respond to treatment, corneal biopsy may be necessary.
Management requires urgent and aggressive therapy. First-line treatment for suspected bacterial ulcers involves intensive topical antibiotics, typically fourth-generation fluoroquinolones administered frequently, even hourly. Severe or resistant cases may require fortified antibiotics such as vancomycin combined with tobramycin or ceftazidime. Therapy should be adjusted based on culture results. If the ulcer is unresponsive or atypical, alternative diagnoses such as fungal or Acanthamoeba keratitis must be considered, and appropriate antifungal or anti-protozoal agents initiated.
Adjunctive therapy includes cycloplegic agents to relieve pain and prevent synechiae, as well as lubricating ointments to support epithelial healing. Systemic therapy may be required in certain infections, such as Neisseria or severe fungal disease. Referral to a cornea specialist is indicated if the ulcer is central, progressive, unresponsive to treatment within 24–48 hours, or difficult to culture.
Close follow-up is essential, typically on a daily basis until the ulcer stabilizes. Signs of improvement include re-epithelialization, reduction in infiltrate density, resolution of hypopyon, stabilization of corneal thickness, and improvement in visual acuity and symptoms. Early and appropriate management is critical to prevent complications such as corneal scarring, perforation, and permanent vision loss.
- Published on
Ophthalmology – Central and Branch Retinal Artery Occlusion (CRAO & BRAO)
Central and branch retinal artery occlusions are ophthalmic emergencies caused by interruption of blood flow to the inner retina. The central retinal artery supplies the inner retinal layers, and its occlusion (CRAO) results in profound ischemia, whereas occlusion of a branch retinal artery (BRAO) leads to localized retinal infarction. Both conditions typically present with sudden, painless, monocular vision loss, although the severity varies depending on the location and extent of the occlusion.
These conditions are strongly associated with systemic vascular risk factors such as hypertension, diabetes mellitus, carotid artery atherosclerosis, cardiac valvular disease, and hypercoagulable states. The underlying mechanism involves loss of retinal perfusion leading to ischemia and infarction. The most common cause is embolism, with different types of emboli including cholesterol (Hollenhorst plaques), platelet-fibrin, calcium, fat, septic emboli, and others. Additional causes include thrombosis, vasculitis such as giant cell arteritis, vasospasm, trauma, and systemic diseases like sickle cell anemia or autoimmune disorders.
Patients typically present with acute, painless vision loss in one eye. In CRAO, the vision loss is usually severe, often reduced to counting fingers or light perception. In contrast, BRAO may present with partial visual loss, scotomas, or even be asymptomatic if the macula is spared. Some patients report transient vision loss episodes (amaurosis fugax) prior to the event. In older patients, symptoms such as headache, jaw claudication, and scalp tenderness raise concern for giant cell arteritis, which requires urgent evaluation.
On examination, a relative afferent pupillary defect is commonly present, particularly in CRAO. Fundoscopic findings in CRAO include diffuse retinal whitening and edema in the posterior pole with the classic “cherry-red spot” at the fovea. This occurs because the fovea is supplied by the choroidal circulation and remains relatively spared. In BRAO, retinal whitening is localized to the distribution of the affected artery. Emboli may sometimes be visualized within retinal arterioles, and the blood column may appear segmented, known as “boxcarring,” indicating poor perfusion.
Diagnosis involves both ocular and systemic evaluation. Laboratory tests include complete blood count, inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein, lipid profile, and blood glucose. Additional testing may be required to evaluate for hypercoagulable states or infectious causes. Imaging studies such as fluorescein angiography can demonstrate delayed arterial filling, while carotid ultrasound, echocardiography, and electrocardiography are important for identifying the source of emboli. If giant cell arteritis is suspected, urgent temporal artery biopsy is indicated.
Management options for CRAO and BRAO are limited and often yield poor visual outcomes, especially in CRAO. Immediate measures aim to restore retinal perfusion, although their effectiveness is uncertain. These include lowering intraocular pressure with medications such as topical agents or oral acetazolamide, ocular massage to dislodge emboli, and anterior chamber paracentesis. If giant cell arteritis is suspected, high-dose systemic corticosteroids must be initiated immediately to prevent involvement of the fellow eye. Antiplatelet therapy such as aspirin may also be considered.
Long-term management focuses on identifying and controlling systemic risk factors to prevent further vascular events. Patients should be referred for comprehensive cardiovascular evaluation. Follow-up is essential to monitor for complications, particularly neovascularization of the iris or retina, which can lead to neovascular glaucoma. This typically occurs several weeks after the initial event and may require treatment with panretinal photocoagulation or anti-VEGF therapy.
The prognosis differs between CRAO and BRAO. CRAO generally has a poor visual prognosis, with most patients experiencing permanent severe vision loss. In contrast, BRAO has a better outcome, and many patients recover visual acuity to 20/40 or better, especially if the macula is not involved. Complications include neovascular glaucoma, vitreous hemorrhage, and other sequelae of ocular neovascularization.
Early recognition of retinal artery occlusion is critical, not only for potential ocular intervention but also because it may signal underlying systemic vascular disease, including an increased risk of stroke. Prompt multidisciplinary evaluation and management are therefore essential.
Central and branch retinal artery occlusions are ophthalmic emergencies caused by interruption of blood flow to the inner retina. The central retinal artery supplies the inner retinal layers, and its occlusion (CRAO) results in profound ischemia, whereas occlusion of a branch retinal artery (BRAO) leads to localized retinal infarction. Both conditions typically present with sudden, painless, monocular vision loss, although the severity varies depending on the location and extent of the occlusion.
These conditions are strongly associated with systemic vascular risk factors such as hypertension, diabetes mellitus, carotid artery atherosclerosis, cardiac valvular disease, and hypercoagulable states. The underlying mechanism involves loss of retinal perfusion leading to ischemia and infarction. The most common cause is embolism, with different types of emboli including cholesterol (Hollenhorst plaques), platelet-fibrin, calcium, fat, septic emboli, and others. Additional causes include thrombosis, vasculitis such as giant cell arteritis, vasospasm, trauma, and systemic diseases like sickle cell anemia or autoimmune disorders.
Patients typically present with acute, painless vision loss in one eye. In CRAO, the vision loss is usually severe, often reduced to counting fingers or light perception. In contrast, BRAO may present with partial visual loss, scotomas, or even be asymptomatic if the macula is spared. Some patients report transient vision loss episodes (amaurosis fugax) prior to the event. In older patients, symptoms such as headache, jaw claudication, and scalp tenderness raise concern for giant cell arteritis, which requires urgent evaluation.
On examination, a relative afferent pupillary defect is commonly present, particularly in CRAO. Fundoscopic findings in CRAO include diffuse retinal whitening and edema in the posterior pole with the classic “cherry-red spot” at the fovea. This occurs because the fovea is supplied by the choroidal circulation and remains relatively spared. In BRAO, retinal whitening is localized to the distribution of the affected artery. Emboli may sometimes be visualized within retinal arterioles, and the blood column may appear segmented, known as “boxcarring,” indicating poor perfusion.
Diagnosis involves both ocular and systemic evaluation. Laboratory tests include complete blood count, inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein, lipid profile, and blood glucose. Additional testing may be required to evaluate for hypercoagulable states or infectious causes. Imaging studies such as fluorescein angiography can demonstrate delayed arterial filling, while carotid ultrasound, echocardiography, and electrocardiography are important for identifying the source of emboli. If giant cell arteritis is suspected, urgent temporal artery biopsy is indicated.
Management options for CRAO and BRAO are limited and often yield poor visual outcomes, especially in CRAO. Immediate measures aim to restore retinal perfusion, although their effectiveness is uncertain. These include lowering intraocular pressure with medications such as topical agents or oral acetazolamide, ocular massage to dislodge emboli, and anterior chamber paracentesis. If giant cell arteritis is suspected, high-dose systemic corticosteroids must be initiated immediately to prevent involvement of the fellow eye. Antiplatelet therapy such as aspirin may also be considered.
Long-term management focuses on identifying and controlling systemic risk factors to prevent further vascular events. Patients should be referred for comprehensive cardiovascular evaluation. Follow-up is essential to monitor for complications, particularly neovascularization of the iris or retina, which can lead to neovascular glaucoma. This typically occurs several weeks after the initial event and may require treatment with panretinal photocoagulation or anti-VEGF therapy.
The prognosis differs between CRAO and BRAO. CRAO generally has a poor visual prognosis, with most patients experiencing permanent severe vision loss. In contrast, BRAO has a better outcome, and many patients recover visual acuity to 20/40 or better, especially if the macula is not involved. Complications include neovascular glaucoma, vitreous hemorrhage, and other sequelae of ocular neovascularization.
Early recognition of retinal artery occlusion is critical, not only for potential ocular intervention but also because it may signal underlying systemic vascular disease, including an increased risk of stroke. Prompt multidisciplinary evaluation and management are therefore essential.
- Published on
Ophthalmology – Cavernous Sinus Thrombosis (CST)
Cavernous sinus thrombosis (CST) is a rare but potentially life-threatening condition characterized by the formation of a thrombus within the cavernous sinus. It may be septic, aseptic, or vascular in origin. Septic CST results from the spread of infection, most commonly from the paranasal sinuses, dental infections, facial skin infections, or middle ear infections. Aseptic CST occurs in the setting of hypercoagulable states, trauma, or surgery, while vascular causes are often related to carotid–cavernous fistulas. Due to the valveless venous system of the face and orbit, infections can spread retrograde into the cavernous sinus, making this condition particularly dangerous.
Although CST is rare, it carries significant morbidity and mortality. Septic CST was once universally fatal, but with modern treatment, mortality has decreased to approximately 30%. Risk factors vary depending on the etiology. Septic CST often occurs in otherwise healthy individuals with recent head or neck infections, whereas aseptic CST is associated with hypercoagulable states such as antiphospholipid syndrome, malignancy, pregnancy, or inherited thrombophilias. Additional risk factors include diabetes, immunosuppression, trauma, and sinus disease.
The pathophysiology involves obstruction of venous drainage within the cavernous sinus, leading to orbital congestion and impaired cranial nerve function. The cranial nerves that traverse the cavernous sinus—III, IV, V1, V2, and VI—may be affected, resulting in ophthalmoplegia, facial sensory deficits, and visual disturbances. Impaired venous outflow also leads to proptosis, chemosis, and increased intraocular pressure, while severe cases may extend intracranially, causing meningitis, abscess formation, or stroke.
Patients typically present with headache, which is the most common symptom, along with fever in septic cases. A history of sinusitis, dental infection, facial infection, or recent trauma may be elicited. Ocular symptoms include diplopia, decreased vision, and eye pain. On examination, findings often include proptosis, chemosis, eyelid edema, and ophthalmoplegia. Cranial nerve palsies are common, particularly involving the abducens nerve. Trigeminal nerve involvement, especially sensory loss in the V1 or V2 distribution, is an important distinguishing feature from orbital cellulitis. Bilateral orbital involvement is also highly suggestive of CST rather than simple orbital cellulitis.
Diagnosis is primarily clinical, supported by laboratory and imaging studies. Laboratory evaluation includes complete blood count, coagulation profile, blood cultures, and cultures of any suspected infection source. Imaging with CT scan is usually the first step and may show indirect signs such as enlargement of the superior ophthalmic vein or abnormal filling of the cavernous sinus. MRI provides greater sensitivity for detecting thrombus and associated soft tissue changes. However, imaging may not always detect early CST, and a high index of clinical suspicion is essential.
Management of CST is an emergency and requires immediate hospitalization. Septic CST is treated with broad-spectrum intravenous antibiotics, typically a combination of a third-generation cephalosporin and vancomycin, with antifungal therapy added if indicated. Aseptic CST is managed with anticoagulation, while cases related to fistulas may require angiography and endovascular intervention. Surgical drainage of the primary infectious source, such as sinus or dental abscess, is often necessary. The use of anticoagulation in septic CST remains controversial but may be considered in selected cases. Corticosteroids are reserved for specific indications such as pituitary insufficiency.
Close inpatient monitoring is critical, often in an intensive care setting for severe cases. Follow-up care depends on the underlying cause and includes prolonged antibiotic therapy, monitoring for recurrence, and management of any persistent neurologic deficits. Patients with hypercoagulable states may require long-term anticoagulation.
The prognosis of CST depends on its cause and the timeliness of treatment. Septic CST carries a guarded prognosis, with significant mortality and a high rate of long-term neurologic sequelae among survivors. In contrast, CST associated with fistulas generally has a better outcome if treated appropriately. Complications include permanent vision loss, cranial nerve deficits, intracranial infections such as meningitis or encephalitis, hemorrhagic stroke, and death.
Early recognition and prompt treatment are essential to improving outcomes. Key clinical clues include bilateral orbital signs, cranial nerve involvement, and a history of infection or hypercoagulable risk factors. Even in the presence of inconclusive imaging, CST should be strongly considered when clinical suspicion is high, as delays in treatment can lead to devastating consequences.
Cavernous sinus thrombosis (CST) is a rare but potentially life-threatening condition characterized by the formation of a thrombus within the cavernous sinus. It may be septic, aseptic, or vascular in origin. Septic CST results from the spread of infection, most commonly from the paranasal sinuses, dental infections, facial skin infections, or middle ear infections. Aseptic CST occurs in the setting of hypercoagulable states, trauma, or surgery, while vascular causes are often related to carotid–cavernous fistulas. Due to the valveless venous system of the face and orbit, infections can spread retrograde into the cavernous sinus, making this condition particularly dangerous.
Although CST is rare, it carries significant morbidity and mortality. Septic CST was once universally fatal, but with modern treatment, mortality has decreased to approximately 30%. Risk factors vary depending on the etiology. Septic CST often occurs in otherwise healthy individuals with recent head or neck infections, whereas aseptic CST is associated with hypercoagulable states such as antiphospholipid syndrome, malignancy, pregnancy, or inherited thrombophilias. Additional risk factors include diabetes, immunosuppression, trauma, and sinus disease.
The pathophysiology involves obstruction of venous drainage within the cavernous sinus, leading to orbital congestion and impaired cranial nerve function. The cranial nerves that traverse the cavernous sinus—III, IV, V1, V2, and VI—may be affected, resulting in ophthalmoplegia, facial sensory deficits, and visual disturbances. Impaired venous outflow also leads to proptosis, chemosis, and increased intraocular pressure, while severe cases may extend intracranially, causing meningitis, abscess formation, or stroke.
Patients typically present with headache, which is the most common symptom, along with fever in septic cases. A history of sinusitis, dental infection, facial infection, or recent trauma may be elicited. Ocular symptoms include diplopia, decreased vision, and eye pain. On examination, findings often include proptosis, chemosis, eyelid edema, and ophthalmoplegia. Cranial nerve palsies are common, particularly involving the abducens nerve. Trigeminal nerve involvement, especially sensory loss in the V1 or V2 distribution, is an important distinguishing feature from orbital cellulitis. Bilateral orbital involvement is also highly suggestive of CST rather than simple orbital cellulitis.
Diagnosis is primarily clinical, supported by laboratory and imaging studies. Laboratory evaluation includes complete blood count, coagulation profile, blood cultures, and cultures of any suspected infection source. Imaging with CT scan is usually the first step and may show indirect signs such as enlargement of the superior ophthalmic vein or abnormal filling of the cavernous sinus. MRI provides greater sensitivity for detecting thrombus and associated soft tissue changes. However, imaging may not always detect early CST, and a high index of clinical suspicion is essential.
Management of CST is an emergency and requires immediate hospitalization. Septic CST is treated with broad-spectrum intravenous antibiotics, typically a combination of a third-generation cephalosporin and vancomycin, with antifungal therapy added if indicated. Aseptic CST is managed with anticoagulation, while cases related to fistulas may require angiography and endovascular intervention. Surgical drainage of the primary infectious source, such as sinus or dental abscess, is often necessary. The use of anticoagulation in septic CST remains controversial but may be considered in selected cases. Corticosteroids are reserved for specific indications such as pituitary insufficiency.
Close inpatient monitoring is critical, often in an intensive care setting for severe cases. Follow-up care depends on the underlying cause and includes prolonged antibiotic therapy, monitoring for recurrence, and management of any persistent neurologic deficits. Patients with hypercoagulable states may require long-term anticoagulation.
The prognosis of CST depends on its cause and the timeliness of treatment. Septic CST carries a guarded prognosis, with significant mortality and a high rate of long-term neurologic sequelae among survivors. In contrast, CST associated with fistulas generally has a better outcome if treated appropriately. Complications include permanent vision loss, cranial nerve deficits, intracranial infections such as meningitis or encephalitis, hemorrhagic stroke, and death.
Early recognition and prompt treatment are essential to improving outcomes. Key clinical clues include bilateral orbital signs, cranial nerve involvement, and a history of infection or hypercoagulable risk factors. Even in the presence of inconclusive imaging, CST should be strongly considered when clinical suspicion is high, as delays in treatment can lead to devastating consequences.
- Published on
Ophthalmology – Congenital and Infantile Glaucoma
Congenital and infantile glaucoma is a developmental disorder characterized by trabeculodysgenesis, leading to impaired aqueous humor outflow and elevated intraocular pressure (IOP). It presents at birth or within the first 3–4 years of life and must be distinguished from secondary pediatric glaucomas associated with other ocular or systemic conditions.
The condition may be unilateral (25%) or bilateral (75%), and early recognition is critical to prevent permanent visual damage.
Epidemiologically, incidence varies by region. It is more common in certain populations (e.g., parts of the Middle East) and relatively rare in the United States. There is a slight male predominance (3:2), and family history is an important risk factor.
Genetically, about 10% of cases follow an autosomal recessive inheritance pattern. Several loci have been identified, most notably mutations in the CYP1B1 gene. Other genes such as MYOC and LTBP2 may also be involved. Genetic counseling is recommended, especially in familial cases.
Pathophysiologically, abnormal development of the anterior chamber angle structures leads to impaired aqueous drainage. Proposed mechanisms include malformed trabecular meshwork, abnormal insertion of the iris or ciliary body, and abnormalities of Schlemm’s canal. These abnormalities result in increased intraocular pressure, which in infants causes stretching of ocular tissues.
The classic clinical triad includes:
• Epiphora (excessive tearing)
• Photophobia (light sensitivity)
• Blepharospasm (eyelid squeezing)
Additional features include enlarged eyes (buphthalmos), cloudy corneas, and progressive myopia. Corneal enlargement (>12 mm in diameter) and breaks in Descemet’s membrane known as Haab’s striae are characteristic findings.
Examination often requires sedation or anesthesia. Key findings include elevated IOP (typically 25–35 mm Hg), increased axial length, corneal edema, and optic nerve cupping. Unlike adult glaucoma, optic nerve changes in children may be partially reversible if treated early.
Diagnostic evaluation includes tonometry, gonioscopy (to assess angle structures), optic nerve imaging, and sometimes optical coherence tomography. Visual field testing is performed later when the child is developmentally able.
The differential diagnosis includes other causes of tearing (such as nasolacrimal duct obstruction), corneal clouding (e.g., dystrophies, infections), and enlarged cornea (e.g., megalocornea).
Management is primarily surgical, as this is a structural problem. Medical therapy is used only as a temporary or adjunctive measure to lower IOP. First-line medications include topical beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogues. Alpha-2 agonists (like brimonidine) should be avoided in very young children due to risk of central nervous system depression.
The mainstay of treatment is angle surgery:
• Goniotomy – first-line in clear corneas, with ~80% success
• Trabeculotomy – preferred when the cornea is cloudy
If these fail, further options include tube shunts, trabeculectomy, or cyclophotocoagulation in advanced cases.
Supportive care is equally important. This includes correction of refractive errors, treatment of strabismus, and especially prevention of amblyopia, which is the most common cause of visual loss in these patients. Frequent refraction and visual monitoring are essential.
Lifelong follow-up is required. Infants often need examinations every 3–4 months, including periodic exams under anesthesia. Monitoring focuses on IOP control, corneal clarity, optic nerve status, and visual development.
Prognosis depends on early diagnosis and timely surgical intervention. Approximately 80% of patients achieve adequate IOP control, and about 40% may retain good visual acuity (20/40 or better). Outcomes are generally better when surgery is performed between 2–12 months of age.
Complications include visual field loss, amblyopia, refractive errors (myopia, astigmatism), cataract, corneal scarring, and blindness. In severe or untreated cases, the eye may become painful or progress to phthisis bulbi.
- Published on
Ophthalmology – Cone Dystrophy
Cone dystrophy is a progressive retinal disorder characterized by degeneration of cone photoreceptors, leading to the classic triad of central vision loss, photophobia, and dyschromatopsia (color vision impairment). It represents a heterogeneous group of inherited conditions with variability in clinical presentation and genetic causes.
Cone disorders exist along a spectrum. At one end are cone dysfunction syndromes (such as Achromatopsia), which present early in life and are non-progressive. At the other end are cone dystrophies, which are progressive and typically present from childhood to early adulthood. A related group, cone-rod dystrophies, involves both cone and rod degeneration early in the disease course.
The prevalence of cone dystrophy is approximately 1 in 40,000 individuals. A positive family history is a significant risk factor. Although many cases are sporadic, inheritance patterns include autosomal dominant (most common), autosomal recessive, and X-linked recessive forms.
The underlying pathophysiology involves primary degeneration of cone photoreceptors. Because cones are responsible for central vision and color perception, symptoms often appear before any visible retinal changes. All three cone subtypes (responsible for different color wavelengths) are affected, leading to generalized color vision deficits that may progress to complete color blindness. Over time, some patients may also develop secondary rod involvement.
Patients usually present before the age of 20 with progressive decrease in visual acuity, marked photophobia, and early color vision abnormalities. Difficulty distinguishing colors is often one of the earliest signs. If night blindness (nyctalopia) becomes prominent along with these symptoms, a cone-rod dystrophy should be suspected instead.
On examination, findings can be highly variable. The fundus may initially appear normal, especially early in the disease. As the condition progresses, changes may include subtle macular granularity or a characteristic bull’s-eye maculopathy, where a central area of relative preservation is surrounded by a ring of retinal pigment epithelial atrophy. Visual acuity ranges widely, from normal (20/20) to severe impairment. Optic discs may show temporal pallor in advanced cases.
Color vision testing using tools such as the Farnsworth-Munsell 100-Hue test reveals abnormalities across multiple color axes. Visual field testing often demonstrates central scotomas while peripheral fields are relatively preserved.
The most important diagnostic test is the electroretinogram (ERG). Cone dystrophy shows markedly reduced photopic (cone-mediated) responses with relatively preserved or mildly reduced scotopic (rod-mediated) responses. Optical coherence tomography (OCT) may demonstrate disruption or loss of the photoreceptor layer, particularly at the inner segment–outer segment junction. Fundus autofluorescence may show foveal hyperautofluorescence.
The differential diagnosis includes other macular and retinal disorders such as Stargardt disease, hereditary optic atrophies, toxic maculopathy, and cone-rod dystrophies. Distinguishing features include the early and prominent color vision loss and ERG findings.
There is currently no definitive cure for cone dystrophy. Management is primarily supportive. Red-tinted contact lenses may reduce photophobia and improve visual comfort. Patients often benefit from referral to low vision specialists to optimize remaining vision and maintain quality of life.
Emerging therapies, including gene therapy, stem cell therapy, and photoreceptor transplantation, are under investigation but are not yet standard treatments.
Ongoing care includes periodic monitoring of visual acuity, color vision, and retinal function (via ERG). Genetic counseling is important to help patients understand inheritance patterns and risks to family members.
The prognosis is variable. Earlier onset generally correlates with more severe disease and faster progression. Some patients retain functional vision for many years, while others may develop significant visual impairment or blindness.
Complications primarily include progressive vision loss and complete loss of color vision, which can significantly impact daily functioning and independence.
- Published on
Ophthalmology – Commotio Retinae (Berlin’s Edema)
Commotio retinae, also known as Berlin’s edema when involving the macula, is a retinal condition that occurs following blunt ocular trauma. It is characterized by transient whitening or opacification of the retina due to disruption of the outer retinal layers, particularly the photoreceptors. Despite the term “edema,” the primary pathology is not true fluid accumulation but rather structural damage to retinal cells.
Blunt ocular trauma is relatively common, affecting approximately 4.9 per 1,000 individuals annually. This condition is frequently seen in younger males, especially in the setting of sports-related injuries or high-impact activities. It may also occur during household or occupational accidents involving sudden blunt force to the eye.
The main risk factor is any activity with potential for eye trauma, such as contact sports. Preventive strategies include the use of protective eyewear that meets recognized safety standards, such as ANSI-certified goggles for occupational use and ASTM-approved eyewear for sports.
The pathophysiology involves rapid compression and decompression of the globe (coup–countercoup mechanism), leading to shearing forces that disrupt the photoreceptor outer segments and retinal pigment epithelium. This mechanical injury results in the characteristic retinal whitening seen on examination.
Patients typically present with a history of recent blunt trauma to the eye. Visual symptoms vary depending on the location and extent of retinal involvement. Visual acuity may range from normal (20/20) to significantly reduced (as poor as 20/400), particularly if the macula is involved.
On examination, the retina appears opacified and whitish, often with minimal edema. Retinal vessels usually remain normal in appearance, which helps distinguish this condition from vascular occlusions. In some cases, small retinal or preretinal hemorrhages may be present. A thorough dilated fundus examination with scleral depression is essential to rule out associated injuries.
Commotio retinae is often associated with other ocular injuries from trauma, including subconjunctival hemorrhage, eyelid bruising, hyphema, traumatic iritis, angle recession, orbital fractures, Choroidal rupture, and traumatic macular holes.
Optical coherence tomography (OCT) can be helpful in evaluating the extent of damage, particularly in macular involvement. It typically shows hyperreflectivity and disruption at the level of the photoreceptors and retinal pigment epithelium. Fundus photography can also be used for documentation and follow-up.
The differential diagnosis includes conditions that may also present with retinal whitening, such as Central retinal artery occlusion, branch retinal artery occlusion, shallow retinal detachment, and white-without-pressure. Clinical history and examination findings are key to differentiation.
Management is primarily conservative, as commotio retinae usually resolves spontaneously without specific treatment. Observation is the standard approach. Patients should be re-evaluated by an ophthalmologist within 1 to 2 weeks to ensure resolution and to monitor for complications.
Patient education is important. Individuals should be advised to seek immediate care if they develop symptoms suggestive of retinal tear or detachment, such as flashes, floaters, or a curtain-like loss of vision.
The prognosis is generally favorable, especially in cases where the macula is not involved. Most patients experience full recovery without lasting effects. However, macular involvement may lead to persistent visual impairment.
Potential complications include retinal tears, retinal detachment, macular hole formation, and, in some cases, permanent visual loss.
- Published on
Ophthalmology – Coloboma (Eyelid, Iris, Optic Nerve, Retina)
Coloboma is a congenital developmental abnormality resulting from incomplete closure of the embryonic (choroidal) fissure during the fifth week of gestation. The term originates from the Greek word meaning “curtailed” or “mutilated.” It presents as a defect or gap in ocular structures, which may involve the eyelid, iris, retina, choroid, or optic nerve. These defects are typically located inferiorly due to the inferonasal position of the embryonic fissure during development.
The incidence of coloboma is approximately 0.5–0.7 per 10,000 births. It can occur unilaterally or bilaterally with roughly equal frequency. Most cases are sporadic, though inherited forms exist, including autosomal dominant and recessive patterns. Mutations in the PAX2 gene have been identified in a significant proportion of cases and are associated with abnormalities in organs such as the kidney, central nervous system, and ear.
The pathophysiology involves incomplete or abnormal fusion of the embryonic fissure, resulting in absence or maldevelopment of structures such as the iris, retina, and choroid. The extent and location of the defect determine clinical severity and associated complications.
Coloboma is frequently associated with systemic syndromes. Eyelid colobomas may occur in conditions like Treacher Collins syndrome or Goldenhar syndrome. Optic nerve and iris colobomas can be linked to systemic conditions such as Patau syndrome, renal coloboma syndrome, or basal encephalocele. Chorioretinal colobomas are commonly associated with CHARGE syndrome and other multisystem disorders.
Clinical presentation varies widely. Many patients are asymptomatic unless critical structures such as the macula or optic nerve are involved. Eyelid colobomas may lead to exposure-related dry eye. Iris colobomas typically present as an inferonasal “keyhole” pupil and may cause photophobia. Optic nerve colobomas may present with reduced vision, nystagmus, refractive error, or leukocoria. Chorioretinal colobomas appear as well-demarcated white areas in the inferior fundus and may be associated with visual field defects or retinal detachment.
Diagnosis is primarily clinical, based on slit-lamp examination and fundus evaluation. Imaging may be required depending on the subtype. CT or MRI can help assess associated craniofacial or intracranial abnormalities, especially in syndromic cases. B-scan ultrasonography may be used to detect associated cysts or posterior segment abnormalities. Additional investigations such as chromosomal analysis or renal ultrasound may be indicated when systemic involvement is suspected.
Management is largely supportive, as there is no direct treatment for the structural defect. Visual rehabilitation is key and includes correction of refractive error, amblyopia therapy (especially in children), and use of tinted lenses or cosmetic contact lenses for iris defects. Patients with microphthalmia may benefit from scleral shells or orbital expanders.
Surgical intervention is reserved for complications. Strabismus surgery may be performed if ocular misalignment is present. Retinal detachment associated with chorioretinal coloboma requires prompt surgical management, often including laser photocoagulation around the margins of the defect.
Regular follow-up with an ophthalmologist is essential, along with systemic evaluation by pediatricians or internists when syndromic associations are present. Monitoring focuses on visual development, refractive changes, and early detection of complications such as retinal detachment.
The prognosis depends on the size and location of the coloboma. Isolated iris colobomas generally have excellent visual outcomes, whereas optic nerve or extensive chorioretinal colobomas may result in significant and unpredictable visual impairment.
Complications include amblyopia, refractive errors, glaucoma, retinal detachment, and, less commonly, choroidal neovascularization.
- Published on
Ophthalmology – Coloboma
Coloboma is a congenital ocular defect characterized by a cleft or gap in ocular structures due to incomplete closure of the embryonic (choroidal) fissure during early fetal development. It may affect the iris, retina, choroid, or optic nerve, and is typically located in the inferonasal quadrant. Coloboma can occur unilaterally or bilaterally and may be isolated or associated with other ocular or systemic abnormalities.
The condition is relatively uncommon, with an estimated incidence of approximately 2.6 per 10,000 births in the United States. While some cases occur in isolation, a significant proportion are associated with other congenital anomalies or syndromes, particularly CHARGE syndrome, which is one of the most frequently linked multisystem conditions.
Risk factors include genetic mutations, chromosomal abnormalities, and environmental influences during pregnancy. Several genes have been implicated, including PAX6, SHH, and CHD7. Coloboma is also associated with Microphthalmia, and potential environmental contributors include teratogens such as alcohol or thalidomide, as well as vitamin A deficiency during pregnancy. Inheritance patterns vary and may be sporadic, autosomal dominant, autosomal recessive, or X-linked.
The underlying pathophysiology involves failure of closure of the fetal fissure between the 5th and 7th weeks of gestation. This results in defective development of the retinal pigment epithelium, abnormal choroidal formation, and dysplastic overlying retina. The timing and extent of this developmental failure influence both the severity of the ocular defect and the likelihood of associated systemic anomalies.
Clinically, presentation depends on the structures involved. Iris coloboma appears as a characteristic “keyhole” pupil, usually inferonasally. Posterior segment involvement, such as chorioretinal coloboma, presents as a sharply demarcated white excavation in the fundus, sometimes with visible retinal vessels traversing the defect. Visual symptoms may include decreased vision, visual field defects (typically superior scotoma), strabismus, or nystagmus. Some patients may present with leukocoria.
A comprehensive examination is essential, including visual acuity testing, slit-lamp evaluation, and dilated fundus examination. Assessment for amblyopia, refractive error, and retinal detachment is critical. Family members may also require examination, as some cases are asymptomatic but hereditary. Systemic evaluation is important to identify associated anomalies.
Diagnostic investigations may include ocular ultrasound to assess for associated cysts or microphthalmia, and brain MRI if optic nerve involvement or central nervous system abnormalities are suspected. Genetic testing and counseling are recommended, particularly in syndromic or familial cases. Additional systemic investigations such as echocardiography or audiology testing may be indicated depending on associated findings.
Management focuses on maximizing visual potential and monitoring for complications, as there is no direct treatment for the structural defect itself. Amblyopia therapy is often required in children. Patients with significant visual impairment may benefit from low vision rehabilitation. Referral to genetics and pediatric specialists is appropriate when systemic associations are present.
Surgical intervention may be necessary for complications such as retinal detachment, cataract, or strabismus. In severe cases with microphthalmia, ocular prosthetic support may be considered for cosmetic and structural purposes.
Regular follow-up is essential, particularly to monitor for retinal detachment, which is a known complication. Visual development, educational progress, and systemic health should also be monitored over time.
The prognosis varies widely depending on the size and location of the defect. Small anterior colobomas may have minimal visual impact, whereas large posterior colobomas involving the macula or optic nerve can result in significant visual impairment. Associated systemic abnormalities further influence overall outcomes.
- Published on
Ophthalmology – Clinically Significant Diabetic Macular Edema (CSME)
Clinically significant diabetic macular edema (CSME) is a vision-threatening form of diabetic macular edema defined by the Early Treatment Diabetic Retinopathy Study (ETDRS). It is present when there is retinal thickening within 500 microns of the center of the fovea, hard exudates within 500 microns of the foveal center with adjacent retinal thickening, or an area of retinal thickening at least one disc area in size with any part located within one disc diameter of the foveal center. CSME may be focal, resulting from leakage from isolated microaneurysms, or diffuse, due to generalized breakdown of the inner blood-retinal barrier.
CSME is the leading cause of visual loss in patients with diabetes. Its frequency increases with longer duration of diabetes and with more severe diabetic retinopathy. Studies have shown that a substantial proportion of both type 1 and type 2 diabetic patients develop CSME over time, and hundreds of thousands of individuals are affected in the United States alone.
Major risk factors include long-standing diabetes, poor glycemic control, hypertension, hyperlipidemia, nephropathy, proteinuria, and more advanced diabetic retinopathy. In patients with adult-onset diabetes, insulin use has also been associated with higher risk. Pregnancy can accelerate diabetic retinopathy and CSME, so careful ophthalmic monitoring is recommended before and throughout pregnancy.
The pathophysiology of CSME reflects chronic hyperglycemia-induced damage to the retinal microvasculature. This includes pericyte loss, thickening of the capillary basement membrane, endothelial dysfunction, leukostasis, oxidative stress, and increased inflammatory cytokines such as VEGF. These changes lead to breakdown of the blood-retinal barrier and leakage of fluid into the macula. In some cases, vitreomacular traction may also contribute to edema formation.
Patients may not always notice symptoms early, but a careful history should assess diabetes duration and control, insulin dependence, hypertension, lipid disorders, and kidney disease. Clinically, CSME is diagnosed by slit-lamp biomicroscopy, sometimes aided by contact lens examination, which demonstrates retinal thickening in the macular area. The severity of diabetic retinopathy and the presence of vitreomacular interface abnormalities should also be documented.
Ancillary testing is helpful for both evaluation and follow-up. Fluorescein angiography is not necessary to make the diagnosis, but it can identify leaking microaneurysms, diffuse leakage, areas of macular ischemia, and capillary nonperfusion. Optical coherence tomography (OCT) is especially valuable for documenting retinal thickening, identifying epiretinal membranes or vitreomacular traction, and monitoring treatment response. Systemic evaluation should include HbA1c, blood pressure, blood lipids, and renal function.
Treatment begins with optimization of systemic disease, including strict control of blood glucose, blood pressure, and lipids. Traditionally, focal laser photocoagulation has been the first-line ocular treatment and has been shown to reduce the risk of visual loss substantially. More recently, intravitreal anti-VEGF agents such as ranibizumab and bevacizumab have become important options and may be superior to laser alone in many cases. Intravitreal corticosteroids can also be useful, especially in selected patients, though they are generally considered adjunctive therapy.
In cases of diffuse CSME, refractory edema, or associated vitreomacular traction, referral to a vitreoretinal specialist is appropriate. Vitrectomy with membrane peeling may benefit patients with persistent edema related to traction or epiretinal membrane formation. Fenofibrate may also reduce the need for laser in some diabetic patients.
Close follow-up is essential because CSME is often chronic and recurrent. Patients undergoing active treatment are commonly reviewed every 1 to 3 months, and those with severe nonproliferative or proliferative diabetic retinopathy generally require dilated examination every 3 to 4 months. Coordination with the patient’s primary care physician or endocrinologist is an important part of management.
The prognosis depends on the duration and severity of edema, associated retinal ischemia, and response to treatment. Without treatment, many patients experience moderate visual loss over time. Laser therapy significantly lowers this risk, and newer therapies may further improve outcomes.
